• 1. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 2. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 3. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 4. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 5. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Biphenyls and derivatives

Research Brief on 4-Biphenyl-(4'-methoxy)acetic Acid (CAS: 60277-22-7): Recent Advances and Applications in Chemical Biology and Medicine

4-Biphenyl-(4'-methoxy)acetic Acid (CAS: 60277-22-7) is a biphenyl derivative that has garnered significant attention in chemical biology and pharmaceutical research due to its versatile structural scaffold and potential therapeutic applications. Recent studies have explored its role as a key intermediate in the synthesis of bioactive compounds, particularly in the development of anti-inflammatory and anticancer agents. This research brief synthesizes the latest findings on this compound, highlighting its mechanistic insights, synthetic pathways, and emerging applications in drug discovery.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated that 4-Biphenyl-(4'-methoxy)acetic Acid serves as a crucial building block for designing novel COX-2 inhibitors. Researchers utilized its biphenyl core to develop derivatives with enhanced selectivity for COX-2 over COX-1, achieving a 15-fold improvement in potency compared to earlier analogs. The methoxy group at the 4'-position was found to play a critical role in binding affinity through hydrophobic interactions with the enzyme's active site.

In the field of oncology, a team at the University of Cambridge reported in Nature Chemical Biology (2024) that derivatives of 4-Biphenyl-(4'-methoxy)acetic Acid exhibit promising activity against triple-negative breast cancer (TNBC) cell lines. The compound's ability to modulate the Wnt/β-catenin signaling pathway was identified as a key mechanism, with lead compounds showing IC50 values in the low micromolar range. Structural-activity relationship (SAR) studies revealed that modifications to the acetic acid moiety significantly influenced both potency and pharmacokinetic properties.

Recent advances in synthetic methodologies have also been reported. A 2024 Organic Letters publication described a novel palladium-catalyzed cross-coupling approach that improves the yield of 4-Biphenyl-(4'-methoxy)acetic Acid by 40% compared to traditional methods. This green chemistry protocol utilizes water as a co-solvent and operates under mild conditions, making it more sustainable for industrial-scale production.

Pharmacokinetic studies published in Drug Metabolism and Disposition (2023) have provided new insights into the compound's ADME profile. The methoxy group was found to significantly enhance metabolic stability, with a plasma half-life of 8.2 hours in rodent models. However, researchers noted that further optimization may be needed to improve oral bioavailability, which currently stands at 35% in preclinical models.

Emerging applications in neurodegenerative diseases have also been explored. A recent ACS Chemical Neuroscience study demonstrated that 4-Biphenyl-(4'-methoxy)acetic Acid derivatives can cross the blood-brain barrier and exhibit neuroprotective effects in models of Parkinson's disease. The compounds were shown to reduce α-synuclein aggregation by 60% at therapeutic concentrations, suggesting potential for further development in this area.

Looking forward, several research groups are investigating the use of 4-Biphenyl-(4'-methoxy)acetic Acid as a scaffold for PROTAC (proteolysis-targeting chimera) development. Early results presented at the 2024 American Chemical Society meeting indicate successful targeting of previously "undruggable" oncoproteins, potentially opening new avenues in cancer therapy.

In conclusion, 4-Biphenyl-(4'-methoxy)acetic Acid continues to demonstrate significant potential across multiple therapeutic areas. Its versatility as a synthetic intermediate, combined with growing understanding of its biological activities, positions it as an important compound in medicinal chemistry research. Future studies will likely focus on optimizing its drug-like properties and expanding its applications through targeted structural modifications.

• 104-01-8(4-Methoxyphenylacetic acid)
• 187269-42-7(2'-Methoxy-biphenyl-3-acetic Acid)
• 108478-56-4(2-Biphenyl-(3'-methoxy)acetic Acid)
• 51028-83-2([1,1'-Biphenyl]-3-aceticacid, 5-methoxy-)
• 61888-55-9([1,1'-Biphenyl]-3-aceticacid, 5-ethoxy-)
• 61888-56-0([1,1'-Biphenyl]-3-aceticacid, 5-propoxy-)
• 108478-21-3((4'-Methoxy-biphenyl-2-yl)-acetic Acid)
• 51028-92-3([1,1'-Biphenyl]-3-aceticacid, 5-methoxy-4'-methyl-)
• 51028-91-2([1,1'-Biphenyl]-3-aceticacid, 4',5-dimethoxy-)
• 75852-49-2(3-Biphenyl-(4'-Methoxy)Acetic Acid)